Pre-Made Ripafollitropin Alfa (Bovine) biosimilar, Fusion Protein: Recombinant therapeutic protein targeting Bostau FSHR fused with CTP (C-terminal peptide of hCG) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-INN-974

Pre-Made Ripafollitropin Alfa (Bovine) biosimilar, Fusion Protein: Recombinant therapeutic protein targeting Bostau FSHR fused with CTP (C-terminal peptide of hCG) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ripafollitropin Alfa (Bovine) is a recombinant Follicle-stimulating hormone fusion protein with chorionic gonadotropin

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-974-1mg 1mg 3090
GMP-Bios-INN-974-10mg 10mg Inquiry
GMP-Bios-INN-974-100mg 100mg Inquiry
GMP-Bios-INN-974-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Ripafollitropin Alfa (Bovine) biosimilar, Fusion Protein: Recombinant therapeutic protein targeting Bostau FSHR fused with CTP (C-terminal peptide of hCG)
INN Name Ripafollitropin Alfa (Bovine)
TargetBostau FSHR
FormatFusion Protein
Derivationhuman Bos taurus Hybrid
Species Reactivityhuman
CH1 IsotypeFusion - Bos taurus FSH (follicle- stimulating hormone) - CTP (C- terminal peptide of the β-subunit of human chorionic gonadotropin (hCG))
VD LCFusion - Bos taurus FSH (follicle- stimulating hormone) - CTP (C- terminal peptide of the β-subunit of human chorionic gonadotropin (hCG))
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesCeva Santé Animale (Bordeaux France)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0